Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Hang Quach, MD, Simon Harrison, MD, Liam J. Fernyhough, MB, BS, BMedSci, Ross Alistair Henderson, PhD FRACP, FRCPA, Gillian Corbett, MDFRACP FRCPA, Peter Browett, MBChB, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Craig Underhill, MD, Paul Cannell, MD, Judith Trotman, MBChB, Emma Link, Linda Cowan, Jack S Li, Meletios A. Dimopoulos, H. Miles Prince, MD

Blood (2015) 126 (23): 4236.

https://doi.org/10.1182/blood.V126.23.4236.4236

Published: 2015

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Melita K Kenealy, MBBS, FRACP, FRCPA, John F Seymour, MBBS, PhD, FRACP, Cowan Linda, Alvin Milner, Pratyush Giri, Shir-Jing Ho, MBBS, FRACP, FRCPA, Warwick Benson, Andrew Nicol, MBBS, FRCPA, FRACP, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Craig Underhill, MBBS, FRACP, Ilona Cunningham, Anthony K. Mills, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Peter Presgrave, MBBS, FRACP, FRCPA, PhD, Robin Filshie, MBChB, FRACP, FRCPA, PhD

Blood (2009) 114 (22): 1749.

https://doi.org/10.1182/blood.V114.22.1749.1749

Published: 2009

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

Noemi Horvath, MB, ChB, FRACP, FRCPA, Douglas E. Joshua, D. Phil FRACP, John Gibson, MD, Andrew W. Roberts, MBBS, PhD, John Norman, MBBS, FRACP, Craig Underhill, MBBS, FRACP, David M. Ross, MBBS, FRACP, FRCPA, Sonya Stephens, Trevor Rawling, Luen B. To, MD

Blood (2005) 106 (11): 5162.

https://doi.org/10.1182/blood.V106.11.5162.5162

Published: 2005

Journal Articles

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

Andrew Spencer, DM, Andrew Grigg, MBBS, John Catalano, MBBS, Michael Leahy, MBBS, Craig Underhill, MBBS, Chris Arthur, MBBS, James DRozario, MBBS, Ray Lowenthal, DM, Kerry Taylor, MBBS

Blood (2005) 106 (11): 3336.

https://doi.org/10.1182/blood.V106.11.3336.3336

Published: 2005

Journal Articles

A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.

Andrew Spencer, DM, John Catalano, FRACP, Andrew Grigg, FRACP, Michael Leahy, FRACP, Craig Underhill, FRACP, Vinod Ganju, FRACP, Christopher Arthur, FRACP

Blood (2004) 104 (11): 4597.

https://doi.org/10.1182/blood.V104.11.4597.4597

Published: 2004

Journal Articles

A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).

Constantine S. Tam, MBBS, John Francis Seymour, MBBS, Michael Brown, RN, Philip Campbell, MBBS, John D. Scarlett, MBBS, Craig Underhill, MBBS, David Ritchie, MBBS, Rodney Bond, MBBS, Andrew Grigg, MBBS

Blood (2004) 104 (11): 3313.

https://doi.org/10.1182/blood.V104.11.3313.3313

Published: 2004

Journal Articles

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age

Linda Mileshkin, James J. Biagi, Paul Mitchell, Craig Underhill, Andrew Grigg, Richard Bell, Joe McKendrick, Peter Briggs, John F. Seymour, Kate Lillie, Jennifer G. Smith, Jerome B. Zeldis, H. Miles Prince

Blood (2003) 102 (1): 69–77.

https://doi.org/10.1182/blood-2002-09-2846

Published: 2003

NARROW

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.

A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only